TELA (telabio.com) Short-Term Debt to Capital

TELA Bio, Inc. (TELA) generates revenue by creating collagen meshes for hernia repair, investing in complex R&D and production automation. The innovative nature of these materials allows the company to maintain pricing power by leveraging the safety of the procedures. This chart illustrating the change in short-term liabilities to capital reflects 0.00. Stable demand for implants ensures a regular cash flow, while the absence of technological obsolescence confirms the business growth.

Managing short-term liabilities is critical for TELA Bio, Inc. (TELA), as scaling sales of OviTex grafts requires significant working capital. By analyzing the current short-term debt to equity ratio, an investor assesses the proportion of "fast" loans relative to equity, where a sharp increase in the metric indicates liquidity risk, while its decline confirms the business's financial autonomy.